First Time Loading...
N

NeoPharm Co Ltd
KOSDAQ:092730

Watchlist Manager
NeoPharm Co Ltd
KOSDAQ:092730
Watchlist
Price: 24 750 KRW -4.62% Market Closed
Updated: May 14, 2024

Intrinsic Value

NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. [ Read More ]

The intrinsic value of one NeoPharm Co Ltd stock under the Base Case scenario is 25 090.58 KRW. Compared to the current market price of 24 750 KRW, NeoPharm Co Ltd is Undervalued by 1%.

Key Points:
Intrinsic Value
Base Case
25 090.58 KRW
Undervaluation 1%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation Backtest
NeoPharm Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NeoPharm Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
NeoPharm Co Ltd

Provide an overview of the primary business activities
of NeoPharm Co Ltd.

What unique competitive advantages
does NeoPharm Co Ltd hold over its rivals?

What risks and challenges
does NeoPharm Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for NeoPharm Co Ltd.

Provide P/S
for NeoPharm Co Ltd.

Provide P/E
for NeoPharm Co Ltd.

Provide P/OCF
for NeoPharm Co Ltd.

Provide P/FCFE
for NeoPharm Co Ltd.

Provide P/B
for NeoPharm Co Ltd.

Provide EV/S
for NeoPharm Co Ltd.

Provide EV/GP
for NeoPharm Co Ltd.

Provide EV/EBITDA
for NeoPharm Co Ltd.

Provide EV/EBIT
for NeoPharm Co Ltd.

Provide EV/OCF
for NeoPharm Co Ltd.

Provide EV/FCFF
for NeoPharm Co Ltd.

Provide EV/IC
for NeoPharm Co Ltd.

Show me price targets
for NeoPharm Co Ltd made by professional analysts.

What are the Revenue projections
for NeoPharm Co Ltd?

How accurate were the past Revenue estimates
for NeoPharm Co Ltd?

What are the Net Income projections
for NeoPharm Co Ltd?

How accurate were the past Net Income estimates
for NeoPharm Co Ltd?

What are the EPS projections
for NeoPharm Co Ltd?

How accurate were the past EPS estimates
for NeoPharm Co Ltd?

What are the EBIT projections
for NeoPharm Co Ltd?

How accurate were the past EBIT estimates
for NeoPharm Co Ltd?

Compare the revenue forecasts
for NeoPharm Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of NeoPharm Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of NeoPharm Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of NeoPharm Co Ltd compared to its peers.

Compare the P/E ratios
of NeoPharm Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing NeoPharm Co Ltd with its peers.

Analyze the financial leverage
of NeoPharm Co Ltd compared to its main competitors.

Show all profitability ratios
for NeoPharm Co Ltd.

Provide ROE
for NeoPharm Co Ltd.

Provide ROA
for NeoPharm Co Ltd.

Provide ROIC
for NeoPharm Co Ltd.

Provide ROCE
for NeoPharm Co Ltd.

Provide Gross Margin
for NeoPharm Co Ltd.

Provide Operating Margin
for NeoPharm Co Ltd.

Provide Net Margin
for NeoPharm Co Ltd.

Provide FCF Margin
for NeoPharm Co Ltd.

Show all solvency ratios
for NeoPharm Co Ltd.

Provide D/E Ratio
for NeoPharm Co Ltd.

Provide D/A Ratio
for NeoPharm Co Ltd.

Provide Interest Coverage Ratio
for NeoPharm Co Ltd.

Provide Altman Z-Score Ratio
for NeoPharm Co Ltd.

Provide Quick Ratio
for NeoPharm Co Ltd.

Provide Current Ratio
for NeoPharm Co Ltd.

Provide Cash Ratio
for NeoPharm Co Ltd.

What is the historical Revenue growth
over the last 5 years for NeoPharm Co Ltd?

What is the historical Net Income growth
over the last 5 years for NeoPharm Co Ltd?

What is the current Free Cash Flow
of NeoPharm Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for NeoPharm Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
NeoPharm Co Ltd

Current Assets 134.5B
Cash & Short-Term Investments 112B
Receivables 10.4B
Other Current Assets 12.1B
Non-Current Assets 43B
Long-Term Investments 10.3B
PP&E 29.2B
Intangibles 2.2B
Other Non-Current Assets 1.2B
Current Liabilities 16.9B
Accounts Payable 6.4B
Other Current Liabilities 10.5B
Non-Current Liabilities 487.8m
Long-Term Debt 430m
Other Non-Current Liabilities 57.7m
Efficiency

Earnings Waterfall
NeoPharm Co Ltd

Revenue
97.1B KRW
Cost of Revenue
-31.7B KRW
Gross Profit
65.4B KRW
Operating Expenses
-40.1B KRW
Operating Income
25.3B KRW
Other Expenses
-2.1B KRW
Net Income
23.2B KRW

Free Cash Flow Analysis
NeoPharm Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

Profitability Score
Profitability Due Diligence

NeoPharm Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROIC
69/100
Profitability
Score

NeoPharm Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

NeoPharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

NeoPharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
NeoPharm Co Ltd

Wall Street analysts forecast NeoPharm Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 36 000 KRW .

Lowest
Price Target
Not Available
Average
Price Target
36 000 KRW
45% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
NeoPharm Co Ltd

1M 1M
+8%
6M 6M
+3%
1Y 1Y
+13%
3Y 3Y
-21%
5Y 5Y
-48%
10Y 10Y
+345%
Annual Price Range
24 750
52w Low
19 850
52w High
29 100
Price Metrics
Average Annual Return -19.23%
Standard Deviation of Annual Returns 13.86%
Max Drawdown -70%
Shares Statistics
Market Capitalization 193.6B KRW
Shares Outstanding 7 820 627
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

NeoPharm Co Ltd

Country

Korea

Industry

Consumer products

Market Cap

193.6B KRW

Dividend Yield

2.69%

Description

NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.

Contact

DAEJEON
DAEJEON
309-8, Techno 2-ro, Yuseong-gu
+82428640038
http://neopharm.co.kr/

IPO

2007-01-30

Employees

-

Officers

Chief Exec. Officer and Pres
Byeong-Deog Park

See Also

Discover More
What is the Intrinsic Value of one NeoPharm Co Ltd stock?

The intrinsic value of one NeoPharm Co Ltd stock under the Base Case scenario is 25 090.58 KRW.

Is NeoPharm Co Ltd stock undervalued or overvalued?

Compared to the current market price of 24 750 KRW, NeoPharm Co Ltd is Undervalued by 1%.